22nd Century Basic EPS 2011-2024 | XXII
22nd Century basic eps from 2011 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
| 22nd Century Annual Basic EPS |
| 2023 |
$-116.48 |
| 2022 |
$-74.40 |
| 2021 |
$-50.38 |
| 2020 |
$-33.58 |
| 2019 |
$-50.38 |
| 2018 |
$-14.39 |
| 2017 |
$-31.18 |
| 2016 |
$-35.98 |
| 2015 |
$-38.38 |
| 2014 |
$-62.37 |
| 2013 |
$-143.93 |
| 2012 |
$-52.77 |
| 2011 |
$-11.99 |
| 2010 |
$-26.39 |
| 22nd Century Quarterly Basic EPS |
| 2024-06-30 |
$-0.21 |
| 2024-03-31 |
$-2.94 |
| 2023-12-31 |
$-12.30 |
| 2023-09-30 |
$-58.88 |
| 2023-06-30 |
$-23.81 |
| 2023-03-31 |
$-21.49 |
| 2022-12-31 |
$-32.17 |
| 2022-09-30 |
$-15.04 |
| 2022-06-30 |
$-15.20 |
| 2022-03-31 |
$-11.99 |
| 2021-12-31 |
$-21.59 |
| 2021-09-30 |
$-14.39 |
| 2021-06-30 |
$-7.20 |
| 2021-03-31 |
$-7.20 |
| 2020-12-31 |
$-9.60 |
| 2020-09-30 |
$-7.20 |
| 2020-06-30 |
$-9.60 |
| 2020-03-31 |
$-7.20 |
| 2019-12-31 |
$-11.99 |
| 2019-09-30 |
$-19.19 |
| 2019-06-30 |
$-14.39 |
| 2019-03-31 |
$-4.80 |
| 2018-12-31 |
$-16.79 |
| 2018-09-30 |
$11.99 |
| 2018-06-30 |
$-11.99 |
| 2018-03-31 |
$2.40 |
| 2017-12-31 |
$-7.20 |
| 2017-09-30 |
$-7.20 |
| 2017-06-30 |
$-9.60 |
| 2017-03-31 |
$-7.20 |
| 2016-12-31 |
$-9.60 |
| 2016-09-30 |
$-7.20 |
| 2016-06-30 |
$-9.60 |
| 2016-03-31 |
$-9.60 |
| 2015-12-31 |
$-9.60 |
| 2015-09-30 |
$-9.60 |
| 2015-06-30 |
$-4.80 |
| 2015-03-31 |
$-14.39 |
| 2014-12-31 |
$-21.59 |
| 2014-09-30 |
$-11.99 |
| 2014-06-30 |
$-7.20 |
| 2014-03-31 |
$-21.59 |
| 2013-12-31 |
$-47.98 |
| 2013-09-30 |
$-76.76 |
| 2013-06-30 |
$-2.40 |
| 2013-03-31 |
$-16.79 |
| 2012-12-31 |
$-31.18 |
| 2012-09-30 |
$-2.40 |
| 2012-06-30 |
$0.00 |
| 2012-03-31 |
$-19.19 |
| 2011-12-31 |
$9.60 |
| 2011-09-30 |
$-4.80 |
| 2011-06-30 |
$-9.60 |
| 2011-03-31 |
$-7.20 |
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Consumer Staples |
Tobacco Products |
$0.005B |
$0.032B |
|
22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York.
|
